International Consolidated Companies, Inc. recently signed a letter of intent to acquire businesses with unaudited USD $40 million in revenue, USD $4 million net profit, and USD $50 million in assets. Included in the letter is the acquisition of Hebei Jiasheng Pharmaceutical & Chemical Limited Co. and its subsidiaries located in Shijiazhuang City, Hebei Province Peoples Republic of China.
The company and its subsidiaries amount to over 21 years of experience and host a strong management team. Currently, the company employs over one-thousand people, and brings an extended background in research, sales, and manufacturing. With the manufacturing and selling of biopharmaceutical compounds to the United States and European markets, the company has begun to establish markets for their products in key foreign countries.
Having a clear and sensible corporate vision, the company plans to expand into already existing markets with new and existing products. Attaining a vast knowledge of the marketplace and regulatory compliant operation, combined with their sales and marketing expertise, gives the company a clear competitive edge. Incorporating the International Consolidated Companies, Inc. family, the company is steadily growing with the reputation in China for attracting well managed and highly respected quality companies.
Let us hear your thoughts below: